BENDALIEVA 100 mg contains Bendamustine Hydrochloride, a unique alkylating antineoplastic agent with properties of both alkylating agents and purine analogues. It causes DNA cross-linking, leading to inhibition of DNA replication and cancer cell death. It is mainly used in hematological malignancies.

Bendamustine is indicated for:

1. Chronic Lymphocytic Leukemia (CLL)

2. Indolent Non-Hodgkin’s Lymphoma (NHL)
    – Especially rituximab-refractory disease

3. Mantle Cell Lymphoma (MCL)

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Fatigue

•  Fever

Other side effects:

•  Skin rash

•  Infusion-related reactions

Serious side effects:

•  Severe infections

•  Tumor lysis syndrome

•  Hepatotoxicity

•  Severe skin reactions (rare)

Regular monitoring of CBC, liver and renal function is required.

Dosage depends on indication and patient condition.

Typical dosing:

•  CLL:
    – 100 mg/m² IV on Days 1 and 2, every 28 days

•  NHL / MCL:
   – 120 mg/m² IV on Days 1 and 2, every 21 days

100 mg vial is commonly used for full adult dosing.


NOTE: This medicine should be taken only under a doctor’s supervision.